HIV-2 viral tropism influences CD4 1 T cell count regardless of viral load
暂无分享,去创建一个
E. Poveda | J. Eiros | V. Soriano | C. de Mendoza | C. Rodríguez | E. Caballero | A. Treviño | P. Parra | T. Cabezas | Mariola López | L. Roc | C. D. Mendoza
[1] Soham Gupta,et al. High concordance of genotypic coreceptor prediction in plasma-viral RNA and proviral DNA of HIV-1 subtype C: implications for use of whole blood DNA in resource-limited settings. , 2013, The Journal of antimicrobial chemotherapy.
[2] C. Charpentier,et al. Transmitted drug resistance in French HIV-2-infected patients , 2013, AIDS.
[3] C. Charpentier,et al. Concordance between HIV-2 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA , 2013, AIDS.
[4] C. Charpentier,et al. Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool. , 2012, The Journal of infectious diseases.
[5] C. Charpentier,et al. In Vitro Phenotypic Susceptibility of HIV-2 Clinical Isolates to CCR5 Inhibitors , 2011, Antimicrobial Agents and Chemotherapy.
[6] E. Poveda,et al. Impact of baseline HIV-1 tropism on viral response and CD4 cell count gains in HIV-infected patients receiving first-line antiretroviral therapy. , 2011, The Journal of infectious diseases.
[7] M. Wainberg,et al. Antiretroviral Drug Resistance in Human Immunodeficiency Virus Type 2 , 2009, Antimicrobial Agents and Chemotherapy.
[8] F. Dabis,et al. Title : First year lymphocyte T CD 4 + response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration . Running head : CD 4 response and HIV type in West Africa , 2009 .
[9] F. Brun-Vézinet,et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. , 2008, The Journal of antimicrobial chemotherapy.
[10] B. Gazzard,et al. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] S. Rowland-Jones,et al. Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection , 2008, Expert review of vaccines.
[12] F. Brun-Vézinet,et al. In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors , 2008, Antimicrobial Agents and Chemotherapy.
[13] E. Poveda,et al. Prevalence of X4 tropic HIV‐1 variants in patients with differences in disease stage and exposure to antiretroviral therapy , 2007, Journal of medical virology.
[14] J. Garson,et al. Development and evaluation of a real-time RT-PCR assay for quantification of cell-free human immunodeficiency virus type 2 using a Brome Mosaic Virus internal control. , 2006, Journal of virological methods.
[15] E. Poveda,et al. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors , 2006, AIDS.
[16] E. Poveda,et al. Enfuvirtide, the first fusion inhibitor to treat HIV infection. , 2005, AIDS reviews.
[17] N. Taveira,et al. Evidence for negative selective pressure in HIV-2 evolution in vivo. , 2005, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[18] W. Heneine,et al. Susceptibility of HIV-2, Siv and Shiv to Various Anti-HIV-1 Compounds: Implications for Treatment and Postexposure Prophylaxis , 2004, Antiviral therapy.
[19] R. Doms,et al. Human immunodeficiency virus type 2. , 2002, Journal of General Virology.
[20] R. D’Aquila,et al. Antiretroviral drug resistance in HIV-1 , 1999, Current infectious disease reports.
[21] H. Whittle,et al. Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. , 1998, Journal of human virology.